Alloy Therapeutics is a biotech ecosystem company, facilitating affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. The company's platform is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
10/03/2022 | Series D | $41.74MM | $xx.xx | $736.24MM | 8VC, Mubadala Capital, Thiel Capital, Presight Capital, Founders Fund | |
Price per Share
$xx.xx
Shares Outstanding
1,973,698
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
8VC, Mubadala Capital, Thiel Capital, Presight Capital, Founders Fund
|
||||||
04/02/2021 | Series C | $75MM | $xx.xx | $563.04MM | 8VC, Presight Capital, Peter Thiel, Mubadala Capital, Founders Fund, Gaingels, Luma Bio-IT, Alexandria Venture Investments, Ulysses Diversified Holdings | |
Price per Share
$xx.xx
Shares Outstanding
4,462,950
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
8VC, Presight Capital, Peter Thiel, Mubadala Capital, Founders Fund, Gaingels, Luma Bio-IT, Alexandria Venture Investments, Ulysses Diversified Holdings
|
||||||
05/31/2020 | Series B | $11.25MM | $xx.xx | $91.25MM | Luma Bio-IT, Alexandria Venture Investments, Ulysses Diversified Holdings | |
Price per Share
$xx.xx
Shares Outstanding
3,205,219
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Luma Bio-IT, Alexandria Venture Investments, Ulysses Diversified Holdings
|
||||||
04/13/2020 | Series A-3 | $6.25MM | $xx.xx | $37.31MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,290,235
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
04/13/2020 | Series A-2 | $1.5MM | $xx.xx | $37.31MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,949,906
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
04/13/2020 | Series A-1 | $500,042 | $xx.xx | $37.31MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,444,374
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|